ACADIA Pharmaceuticals Inc. vs Hormel Foods Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Hormel Foods Corp trades at $24.3 (market cap $13.37B). The key difference: Hormel Foods Corp is far larger — about 2.6× ACADIA Pharmaceuticals Inc.'s market cap, and Hormel Foods Corp pays a 4.81% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | HRL | |
|---|---|---|
Market Cap | $5.07B | $13.37B |
Sector | Health | Consumer Staples |
52-Week High | $29.41 | $29.25 |
52-Week Low | $20.06 | $19.74 |
Enterprise Value | $4.19B | $15.37B |
Dividend Yield | — | 4.81% |
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
Hormel Foods (HRL) trades at $24.41, down 1.21% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 28.6x and modest 3.8% net margin, while revenue has been stable around $12B annually. Recent corporate developments include the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
HRL offers defensive appeal with consistent dividends and a 4.6% yield, but faces margin pressure and modest growth prospects. Analyst consensus is Hold with a $26.33 price target, suggesting limited upside. Key risks include consumer spending sensitivity and execution challenges under new leadership.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →